Hayman Salib, MD
Hematology & Oncology · Phillipsburg, NJNPI 1114956067
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $29,004 of the $42,289 with a category attached, or 68.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.0%. Among hematology & oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,462 payments — averaging $28.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Novartis$4K
- Sanofi$3K
- Gilead$2K
- Seagen Inc.$2K
- Johnson & Johnson$2K
- plus $21K from 54 others
Across 298 payments — averaging $3097.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$402K
- AbbVie$185K
- Novartis$114K
- Sanofi US Services Inc.$104K
- Pharmaessentia USA Corporation$64K
- Amgen$54K
What the payments were for
- Consulting fees$7,39117%
- Speaking & faculty fees$5001%
- Travel & lodging$3981%
- Food & beverage$29,00469%
- Education$3,4818%
- Other$1,5154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,289 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 44 | $671,257 |
| BrukinsaZanubrutinib | 37 | $546,554 |
| Lenalidomide | 29 | $532,346 |
| JakafiRuxolitinib Phosphate | 20 | $338,815 |
| Neulasta OnproPegfilgrastim | 26 | $312,515 |
| NplateRomiplostim | 11 | $311,953 |
| RuxienceRituximab-Pvvr | 11 | $310,343 |
| KeytrudaPembrolizumab | 18 | $298,894 |
| PomalystPomalidomide | 11 | $254,367 |
| IbrancePalbociclib | 16 | $252,819 |
| RituxanRituximab | 17 | $250,230 |
| ProcritEpoetin Alfa | 55 | $184,065 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $100,350 |
| Abiraterone Acetate | 21 | $61,866 |
| EliquisApixaban | 77 | $51,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerRuxience, Ibrance, Octagam, Eliquis, Retacrit | $1,366 | $767,228170 claims |
| AstraZenecaCalquence | $6,778 | $671,25744 claims |
| Beigene USA, Inc.Brukinsa | $231 | $546,55437 claims |
| AmgenNplate, Prolia | $568 | $339,68027 claims |
| Incyte CorporationJakafi | $1,137 | $338,81520 claims |
| MerckKeytruda | $554 | $298,89418 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,566 | $254,36711 claims |
| Genentech, Inc.Rituxan | $238 | $250,23017 claims |
| Johnson & JohnsonProcrit, Xarelto | $1,804 | $195,73070 claims |
| GSKShingrix | $509 | $5,29028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Phillipsburg
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.